Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million on Feb. 26 in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA submission.

Invus Opportunities and Flying L Partners co-led the round in collaboration with Falcon Vision. Existing investors New Enterprise Associates and Versant Ventures, as well as new investor Vida Ventures, also participated in the round...